Illumina, Inc. (ILMN) Earnings Call Transcript & Summary
April 30, 2020
Earnings Call Speaker Segments
Jacquie Ross
executiveHello, everyone, and thanks for being with us on this call about our first-quarter 2020 results. I truly hope all of you are staying healthy right now. On today's call, we'll go over the financial figures we published following the market close, and we'll also give you our thoughts on how the business is performing, and then we'll open things up for questions and answers. Should you not yet have looked at the earnings release, you can access it on our website, illumina.com, under the Investor Relations tab. Here with Illumina today are Francis deSouza, our President and Chief Executive Officer, and Sam Samad, our Chief Financial Officer. Francis is going to give everyone an update on the business, and Sam is going to walk through the financial results. Naturally, since we're dialing in from several places today, please be patient with us should there be any technical glitches or delays; this call is being recorded, and the audio portion is going to be archived in the Investors section of our website. We intend for all forward-looking statements about our financial results and commercial activity that are made on today's call to receive protection under the Private Securities Litigation Reform Act of 1995. Such forward-looking statements carry risks and uncertainties. What actually happens or what we actually achieve could be materially different from what is projected or discussed. Every forward-looking statement rests on information currently available, and Illumina takes on no obligation to update these statements. To gain a better understanding of the risks and uncertainties that might cause actual results to differ, please see the documents Illumina submits to the Securities and Exchange Commission, such as Illumina's most recent Forms 10-Q and 10-K; with that, I'll hand the call over to Francis.
Francis deSouza
executiveThank you, Jackie. Hello, everyone, and I appreciate you being here this afternoon. It is my genuine wish that all of you and the people you care about remain in good health and out of harm's way while we all navigate this difficult period together. As a company operating on a worldwide scale and a genomics pioneer, Illumina has pledged to make every effort possible to aid the fight against the COVID-19 pandemic, assist patients and public health initiatives, and speed up the process of economic recovery. During the earlier phases of this outbreak, technology from Illumina was employed by Dr. Fan Wu and her team at the Shanghai Public Health Center were the ones who sequenced the initial full viral genome to be made public for the virus that later got the name SARS-CoV-2. Since then, organizations worldwide have relied on Illumina's technology for identifying variants and tracking changes as part of monitoring efforts, for learning about how treatments work and how hosts respond, and for exploring diagnostics based on sequencing along with population-level screening to help employees get back to work. On the monitoring front, Dr. Trevor Bedford of the Fred Hutchinson Cancer Research Center in Seattle, together with Dr. Charles Chiu at UCSF, are among the people who watch how the virus propagates and follow mutations. Additionally, we gave products as donations to the Africa CDC, which will help expand their infectious disease surveillance capabilities built on NGS in the Democratic Republic of Congo, Egypt, Ethiopia, Ghana, Kenya, Mali, Nigeria, Senegal, South Africa and Uganda — and in some of those nations, this brought sequencing capability to them for the very first time. The chances of being susceptible to COVID-19 are almost certainly influenced in part by genetics. Understanding how the genetics of both the virus and the host interact is hugely important, since it could allow us to identify those facing the highest risk and help with the development of treatments and vaccines. We're funding a lot of joint efforts with our partners—the New York Genome Center, Stanford, Adaptive Biotechnology, and Genomics England are among them—to get a deeper understanding of how the viral genome evolves and which genetic elements might shape someone's immune response. Just a few days ago, Genomics Medicine Ireland announced it would be sequencing COVID-19-positive samples to identify the factors that raise or lower a person's risk for the disease. On the testing side, PCR and serology-based methods will handle the bulk of it, but plenty of groups are looking at NGS as a way to run multiplex testing. Take IDbyDNA, one of the partners we work with: they offer testing built on NGS that's clinically validated. In addition, multiple groups are releasing papers that describe how NGS assays perform, with plans for clinical validation. Lastly, certain customers are developing ultra-high throughput NGS-based screening tests intended for return to work. Though these efforts remain at an early stage, our teams are striving to assist customers in meeting the testing challenges identified as essential to let our economies recover in a sustainable way without putting individuals in danger. As we back our customers' efforts, the innovations produced by the Illumina team never fail to impress me, though they seldom come as a surprise. In order to assist with COVID-19 efforts, we've put out several workflows and data analytics tools that aid in recognizing the virus and following how it spreads. The following are among them: a shotgun metagenomics use case enabling academics and researchers to identify and describe SARS-CoV-2 as well as additional emerging pathogens in service of epidemiology. Beyond that, this use case makes possible unbiased discovery of simultaneous infections and gene expression analysis of the host's response, allowing study of co-morbidities alongside human immune reaction. There is also an enrichment process built for Public Health Labs, letting them obtain extremely precise SARS-CoV-2 detection together with viral sequence data, which supports better containment planning and identification of other respiratory virus co-infections that may require alternative therapies. Another offering is an amplicon workflow for Public Health Labs examining SARS-CoV-2 epidemiology involving co-infections at greater sample throughput. Finally, a newly introduced software toolkit eases the effort of researchers aiming to find and recognize SARS-CoV-2 viral sequences and contribute their results to public databases. Anyone who owns an Illumina sequencer can get this toolkit free of charge. Unlocking the genome's power to better human health is Illumina's mission, and that mission matters more today than it ever has. Our global team deserves my thanks for their commitment to protecting fellow employees, to keeping supply flowing for customers doing essential work — COVID-19-related or otherwise — and to doing all we can in the fight against this pandemic. I'd also like to acknowledge the numerous Illumina customers and partners engaged directly in the battle against COVID-19. Your energy, ingenuity and dedication inspire us, and we'll do everything within our power to help your efforts have the greatest possible impact. Now I'll give you our quarterly update. Illumina's revenue for the first quarter came in at $859 million, which was above the guidance range we had provided of $850 million to $855 million. Obviously, this quarter involved a great deal of change and complexity, so I'll discuss our business from three angles — geography, customer type, and product — to pass along much of what we've learned. Let's begin with the regions. COVID-19 hit China first, and as a result, that region saw the heaviest impact during the quarter. As the outbreak spread, our focus was on helping customers expand their capacity for work connected to COVID-19. During the first quarter, we placed iSeq and MiSeq platforms beginning in January at a CDC facility located in the area most severely affected, while also providing assistance to additional CDC sites and hospitals nationwide. Once China began enforcing steps aimed at stopping the spread of COVID-19, patients found it hard to keep their scheduled visits for oncology care and NIPT testing. Consequently, demand for both our sequencers and related consumables in China came in below forecast for Q1, with overall revenue from that country reaching $84 million. In China, we began noticing higher run volumes during March and April. While operations aren't fully back to normal, research and clinical customers alike are returning to their labs there and expanding what they're doing. Through much of Q1, EMEA and AMR performed solidly despite COVID-19, and February numbers exceeded our forecasts. Mid-March brought a rapid shift, as a wave of shutdowns and stay-at-home orders rolled across those regions in the closing weeks. Despite that, EMEA and AMR finished Q1 above the targets we'd set, although COVID-19 clearly made an impact. To start with, in both AMR and EMEA, total system shipments came in below what we had anticipated. Systems are usually weighted toward the end of whichever quarter you look at, and for a lot of customers, buying systems simply wasn’t seen as a top priority as Q1 drew to a close. Next, we observed certain customers building up sequencing consumables ahead of time as a precaution. EMEA’s total revenue reached $221 million, while AMR’s total revenue came to $477 million. Last, APJ posted revenue of $77 million, with healthy growth in sequencing consumables, helped by record shipments in Japan, even with headwinds stemming from COVID-19; as a matter of fact, it was a record quarter for APJ as a whole, marking the largest total revenue that region has ever reported. We anticipate Q2 will be a very difficult quarter, with revenue falling from one quarter to the next in every region, though less sharply in China. On a brighter side, Illumina’s operations have continued running worldwide, and thus far we have managed to get past any COVID-19 related difficulties and get products to our customers reliably and on time.
Francis deSouza
executiveTurning now to how things look from the customer side, it's obvious that different customers are feeling COVID-19's effects in different ways, and we've gathered some insights from the number of runs coming through our connected sequencing system network. Not every one of our systems is connected, but we see this as a helpful reference point that illustrates the broader activity pattern across our installed base. Runs get reported no matter how much sequencing output they produce, and they don't correlate directly with revenue. To start, research and clinical runs alike were building momentum nicely through the quarter, hitting their peak in the week that ended March 14th. As you'd expect, research and applied run counts began to ease off in the week that started March 15th, particularly at academic institutions. That mirrors research labs pulling back because of shelter-in-place mandates, among those not engaged directly in COVID-19 work. The drop was steep during the back half of March, yet it leveled off fairly fast, and things have stayed more or less flat from the start of April onward. On the whole, research volume is now at approximately 55% of its level in the fourth quarter of 2019. Switching to clinical, run volume took a hit from COVID-19 too, though it held up a bit better than research did. Clinical runs likewise hit their quarterly apex in the week that ended March 14th. During the week that began March 15th, clinical run volumes began falling, though at a slower pace than research experienced. In contrast to certain research customers, a large number of our clinical customers count as essential healthcare services and have kept operating, even if sample volume suffers as patients steer clear of healthcare facilities. Though smaller in scale, the clinical decreases lasted four weeks, and stabilization began to appear in the week that started April 12th. Clinical volume right now sits at slightly above 80% of its fourth quarter level from last year; to sum up, the curve's shape has differed somewhat between research and clinical customers. Research run volume fell more quickly, yet it also stabilized sooner, and it's been approximately flat across the last four weeks. Clinical run volume's decline was gentler, but it lasted longer before stabilizing over the last two weeks. Both research and clinical run volume rose modestly on a sequential basis in the week that began April 19, though it's plainly too soon to identify any sort of trend. Lastly, turning to the revenue picture, total sequencing system revenue came to $79 million, a decline of 25% versus the same quarter a year ago, and well under our expectations because of COVID-19 disruption. If we set aside COVID-19's effect on sequencing systems, we would have comfortably beaten our sequencing system revenue expectation for the quarter. Even so, system shipments declined across every family, apart from NextSeq 2000 in its first quarter of launch. Our first customer shipments of NextSeq 2000 arrived precisely on schedule on March 9. During the first quarter, system orders matched what we had projected internally; however, shipments came in below what we anticipated as a result of COVID-19 related interruptions late in the period. Among the early adopters of the NextSeq 2000 were customers who already used Illumina as well as new ones, spanning research and academic institutions throughout all four regions. The first applications for the NextSeq 2000 covered food safety, genetic disease, cancer, and research into COVID-19. No new NextSeq 2000 units went out to HiSeq conversion customers during the first quarter. So far, the sales funnel aligns with what we anticipate, which is quite limited cannibalization of NovaSeq conversions among the HiSeq customers who remain in upcoming quarters. Lastly, nearly 50% of the new NextSeq 2000 instruments that shipped went to customers who were quite new to Illumina systems, which exceeded what we had anticipated. Revenue from sequencing consumables reached $553 million, an increase of 15% versus the same quarter a year ago, and it surpassed our expectations. Under 50% of the sequencing consumable outperformance stemmed from COVID-19 related stocking among our clinical customers. NovaSeq pull-through for each system exceeded the same quarter last year and sat easily inside the prior guidance range of $1.1 million to $1.2 million per NovaSeq annually; we do anticipate NovaSeq pull-through will decline substantially in the second quarter. Pull-through for MiSeq along with our NextSeq 500 and 550s remained level compared with the prior quarter, while MiniSeq fell short of its target pull-through range. Sequencing service and other revenue came to $128 million, rising 13% thanks to greater licensing revenue versus the same quarter a year ago. On the whole, sequencing revenue totaled $760 million, somewhat above what we expected, and accounted for 88% of total revenue. Turning to arrays, total array revenue reached $99 million, a drop of 33% versus the same quarter last year, and matched what we had anticipated for the first quarter. Our array services business rose sequentially as we had expected, reflecting the usual seasonality tied to DTC, yet it fell year-over-year. Array consumables dropped both sequentially and year-over-year, which is in line with what we expect from the DTC market. To sum up, our business took an overall hit of more than $20 million in the first quarter, mainly from sequencing instruments, though this was partly offset by a small contribution from COVID-19 related stocking, along with broader strength in sequencing consumables and sequencing service and other. With that, I'll pass it to Sam to go over the financials in greater detail.
Sam Samad
executiveThank you, Francis. I also want to express my appreciation to everyone for being here today. It's my sincere wish that all of you and your loved ones remain in good health and out of harm's way. As we went over, revenue for the first quarter rose 2% compared to the same period a year ago, reaching $859 million, driven slightly by sequencing consumables along with sequencing services and other, which helped counterbalance sequencing system revenue that came in softer than we had anticipated. Turning to gross margin and operating expenses, I'll focus on non-GAAP figures, which incorporate stock-based compensation. I'd urge you to look over the GAAP reconciliation for these non-GAAP metrics, available in today's release as well as the supplementary data posted on our website. Keep in mind that whenever I mention net income and earnings per share from here on, I'm referring to amounts attributable to Illumina shareholders. Our non-GAAP gross margin came in at 73.0%, exceeding what we had projected, as reduced sequencing system revenue paired with greater sequencing consumable and other revenue produced a more favorable mix, and we also benefited from increased fixed cost leverage thanks to higher safety stock volumes. Non-GAAP operating expenses totaled $339 million, which is $33 million lower than the fourth quarter of 2019 and $24 million below the first quarter of 2019. That came in under our expectations because of postponed project spending, decreased labor-related costs, and reduced travel. Non-GAAP operating margin reached 33.6%, climbing from 31.0% in the prior quarter and surpassing our forecast. The non-GAAP tax rate stood at 16.1%, a decline from last quarter and below what we had anticipated, driven by prior year return adjustments and discrete tax benefits tied to the release of tax reserves. For the first quarter of 2020, GAAP net income came to $173 million, or $1.17 per diluted share, while non-GAAP net income was $243 million, or $1.64 per diluted share. Also during the first quarter, cash flow from operations reached $281 million; capital expenditures for the first quarter totaled $40 million, and free cash flow was $241 million. DSO came in at 50 days, versus 55 days in the previous quarter, thanks to better revenue linearity; we closed the quarter with roughly $3.3 billion in cash, cash equivalents, and short-term investments; that's a decrease from the $3.4 billion reported at the close of 2019, reflecting $187 million in share repurchases during the first quarter, plus $132 million for the reverse termination fee and continuation advances paid to Pacific Biosciences. The expenses tied to the PacBio payments are left out of our non-GAAP results. Our weighted average diluted share count for the quarter was about 148 million; we have $563 million remaining available for share repurchases under our current plan. Turning to what lies ahead, we have pulled all of our prior guidance given the uncertainty surrounding how severe and how long the COVID-19 outbreak will be. To put it plainly, that covers our revenue and EPS guidance, along with any other forward-looking remarks we've made regarding NovaSeq or other system portal, NextSeq 1000 and 2000 shipments, and PopGen expectations for the year. One month in, it's clear that the second quarter impact will be considerably larger than what we saw in the first quarter, and we are planning with that in mind. Like I said earlier, we anticipate that revenue will fall on a sequential basis across all geographies during Q2, and the smallest drop in dollars should be in China while AMR sees the biggest. During Q1, we managed to keep production going and get products to customers with only slight delays, yet we do see greater danger of shipping holdups tied to border shutdowns and reduced cargo flight capacity because fewer passenger planes are flying. Once more, none of this is hurting our business right now, though these are forward-looking risks. Because the range of outcomes is so broad, we aren't giving any revenue guidance for Q2 at this point. Although no Q2 guidance is being provided, we can offer a few qualitative remarks regarding elements that will affect our P&L during Q2; for instance, obviously a much smaller top line will pull gross margin down, so a lower gross margin should be anticipated in Q2 both versus the prior quarter and versus a year ago; regarding opex, we stay dedicated to making strategic investments so that we safeguard the resilience of our company once we come out on the other side of the COVID-19 disruption. Consequently, we anticipate that operating expenses will be approximately level in dollar terms relative to Q2 of the prior year. Illumina functions as an innovation engine, and although we have moved some efforts lower on the priority list, we will do whatever is possible to keep our key product development schedules intact; nonetheless, we are watching expenses extremely closely. Over the short term, savings exist from limited discretionary spending, such as travel, marketing events and consulting, plus slower hiring caused by a longer hiring process. We are additionally cutting back on contract and temporary labor spending in some functions. Lastly, we have pushed back selected non-R&D projects and postponed or scrapped particular capital expenditure projects. Relative to our initial budget for this year, Q2 operating expenses have come down by over $40 million; we are likewise getting ready for further cost reduction possibilities should shelter-in-place mandates stay widespread into Q3. Although everyone hopes restrictions will ease soon, we have mapped out multiple scenarios ready to activate if necessary. Throughout the remainder of Q2, we will track the situation closely to judge if more aggressive steps need to be taken faster. This encompasses a thorough reexamination of our capital investment plans and, in certain cases, gating programs. Meanwhile, we keep recruiting and bringing on new team members virtually, while preserving the ability to halt or cap hiring or decelerate other investments should the pandemic drag on. With that, I'll turn the call back to Francis.
Francis deSouza
executiveThanks, Sam. We're keeping in mind how important it is to strike a balance between steering through this pandemic, whose length we can't predict, and making sure we avoid anything that would slow down our innovation pipeline or otherwise get in the way of our capacity to serve our customers' needs. Our hope is that the heaviest impact lands in Q2, while making certain we're fully ready should it stretch into the back half of the year. Difficult as today's conditions are, we see no shift in the long-term path for sequencing adoption and demand. Even in these hard times, clinical testing has shown itself to be fairly resilient, which underscores how important genomic testing is and the medical value it carries. It's accurate that certain labs have put their research work on hold, yet it's equally evident that many research labs are pivoting toward projects tied to COVID-19. Obviously, there's a great deal of work ahead of us to find a way out of this pandemic and then get ready for the next one. It's heartening to observe governments worldwide putting resources behind this vital effort; take, for instance, the two most recent relief packages from the United States government, which directed more than $1 billion to the CDC, aimed specifically at expanding surveillance and other capabilities, in hopes we can be better prepared next time; we don't think any technological barrier stands in the way of accomplishing this; and it's evident that sequencing will sit at the core of the answer; running a business right now is tough. Still, the Illumina community — our employees, our suppliers, our partners and our customers — has never been more united behind a cause or more certain of how much our shared work matters. We're leaving no stone unturned as we aggressively seek out more and more ways to add to the effort; with that, let's begin the Q&A.
Jacquie Ross
executiveDo you have our first question at this time?
Dan Brennan
analystThanks, that's helpful. I'm grateful for the chance to ask, and I hope things go smoothly for you over the coming weeks. There were two things I wanted to cover. First, on the academic end market: can you help us gauge when people doing research at universities will be able to get back into their labs? We'd like to understand the pace at which they could scale activity back up, and related to that, we've heard that making up for lost lab time will be difficult when it comes to consumables, though instrument orders — as we saw — can still be filled. Could you speak to that? Second, I wanted to ask about COVID NGS testing. Clearly, the PCR testing opportunity is drawing plenty of attention, and you touched on some early interest—or maybe the beginnings of an impact—from NGS testing? Might that become a genuine opportunity for Illumina? Any insight you can offer would be useful. Thank you.
Francis deSouza
executiveThanks, Dan. Let me address each of your questions in turn. Your first one concerned the academic market. Once people return to work, how fast will that pick up, and could they potentially make up for delayed consumables or capital purchases? I'll begin there. First, I want to recognize the outstanding efforts put in by several of our customers in academic research during these past few months, which have been quite difficult. I mentioned briefly the efforts of Professor Bedford at the Fred Hutch in Seattle, as well as Charles Chiu at UCSF — our researchers have truly thrown themselves fully into helping us fight the pandemic and grasp how the virus mutates, how it spreads, and how hosts respond. As for how fast that business could scale back up. As long as stay-at-home orders stay in place, that segment will keep taking a hit. Once those orders are removed, though, we anticipate a pretty rapid rebound. The reason is that a portion of the tasks they handle isn't disappearing. So once employees are able to return to their offices — and to their labs — we think they'll resume those projects. And we look for several developments to unfold. First, there are instances—and the UK Biobank is a clear example—where efforts will be made to make up for lost time, yet the nature of their work carries a real sense of urgency. Second, with certain academic clients, we anticipate that extensions will be approved so they can wrap up the projects we've collaborated on within their existing funding periods. And frankly, when we think about research-focused customers, it's hard to imagine circumstances in which the work they do simply goes away. There's also another factor involving blood count that's growing quite evident — namely, research must be conducted on the COVID-19 pandemic itself, in order to grasp matters such as how the viral genome evolves, and truly also to grasp the genetic elements that are — that generate risk, that deliver protective elements for people, to grasp where the virus came from, and there is activity underway in single cell research aimed at grasping how a cell changes once the virus gets inside the cell. So there's a growing need for more studies to be done, and we think both our academic clients and those on the commercial research side will take part in that over this quarter and certainly in the quarters to come. As a result, we expect that work to expand as well. And like I mentioned in the prepared remarks, money has been allocated for the NIH, for the CDC in the UK, and there's research funding for the COVID-19 genomics UK consortium that will back that research; then, on your second question about what NGS can do in COVID-19 testing, there are a number of places where COVID — where NGS is used in testing. To start, as I mentioned in my earlier comments, some of our customers are using NGS-based assays for diagnostic testing. By relying on NGS-based assays, they're adding to the market's overall capacity—that's the first trend we're seeing. Next, we're seeing demand for NGS technology in surveillance work. That's the case at the CDC, starting with the CDC in China, and now it's the case at CDCs around the world; we also recently shipped CDCs to several African countries. So that's another area where NGS is needed for surveillance capabilities. One more opportunity we're seeing involves using extremely high-volume screening to help employees return to their jobs. Our customers are developing ideas around leveraging NGS to deliver that kind of very large-scale screening capacity, so that healthy individuals can get back to work, and in some cases to run ongoing testing that keeps healthy workers on the job. So we're watching that emerge as another potential use case for NGS-based testing. And then last of all, there's an entire area around employing NGS to conduct the research, and whether that's to create further diagnostic tests or for therapies or to grasp host responses, we we're observing that arise as yet another requirement for NGS too.
Sam Samad
executiveSam here, Dan — I’ll give you a single data point. During the opening month of Q2 — the first quarter’s initial month, I mean — instrument shipments to academic institutions have actually come in above what we anticipated. That speaks to how resilient this segment of the market is, even though shelter-in-place remains more of a disruption; therefore, we believe that after we move beyond this pandemic, a rebound will occur, in both instruments and consumable utilization too.
Tycho Peterson
analystThanks. Francis, when we look at the growth drivers you outlined at the start of the year — clearly PopSeq was one, and clinical was another. On PopSeq, I'm wondering if you could update us on the whole NHS UK Biobank situation and how you see some of those initiatives potentially getting back underway. Some of them obviously look like they'll kick off in the back half of the year regardless, but I'd like the latest there. Then on clinical, I appreciate the comment that the clinical decline is broader and lasts longer. We've come across figures showing cancer testing off 25%, 30%. I'm just curious how you view the recovery on the clinical side. And finally, on pandemic surveillance, I'm wondering whether you're doing anything differently from an organizational standpoint or with R&D dollars going forward, if we should be thinking about future pandemics. Thank you.
Francis deSouza
executiveSure; let's take each of those in turn. To begin, here's an update on PopGen. It's evident that shelter-in-place requirements have in fact had an effect on the PopGen programs. I'll address a few of the big ones. As you may have heard from the NHS, we're awaiting revised dates for when they ramp-up. No new dates have been released yet. So we remain engaged with them, and they're assessing their plans for the ramp-up that had been scheduled across the back half of this year. The UK Biobank and <<inaudible>> said in March that they were pausing their sequencing, and they indicated a three month period. There's urgency surrounding that work, so in that effort we anticipate that once they resume sequencing, they'll ramp up very quickly — they had been running at roughly 10,000 genomes a month before the pause, so we expect they can scale that back up quite fast. And they're the sort of customer that would put money in to make up for the sequencing that was missed. Because the data they're getting has value from a therapy perspective, and there's also a finite exclusivity window on that data, so there's urgency around getting back up to speed and catching up. As for all of us here in the U.S., they're currently working through their IDE submission, which we expect shortly to the FDA. And their 270,000 sample cohort is already in place. So really — it's a matter of watching how shelter-in-place requirements come back and people can get back into their labs. But they're making progress on their IDE submission, which is what they're working on. When it comes to the clinical side of the market, like I mentioned during my prepared comments, clinical markets have held up a bit better than the research ones, though they're still running below the level we had in Q4. The main reason is that patients everywhere are reluctant to enter hospitals, and some of them are dealing with their own stay-at-home orders. But the truth is cancer patients still need their testing done, so eventually it will matter for them to return to clinics for oncology tests. Then with NIPT, there's also a sense of time pressure to get tested, and we've seen some loosening on the reimbursement side in the US for covering average risk from some of the bigger carriers, since they understand NIPT is simpler to perform than other options. So even within clinical markets, we anticipate NIPT will hold up better. On pandemic surveillance, we've set up an internal push aimed at building the workflows our customers want across each category I mentioned — diagnostic testing, surveillance, ultra high throughput screening, and research. We've already released three workflows: the shotgun metagenomics one, the enrichment one, and the amplicon one. We've also provided informatics tools to researchers at no cost, which they'd been requesting, to help them analyze COVID-19 data and to make submitting their data to public databases simpler so sharing becomes easier. Right now, these efforts have mostly involved protecting the time of certain staff members working on them, and that's our current approach. So it's more of a shifting of resources than an actual change in R&D spending.
Steve Beuchaw
analystHello, and to begin with, I appreciate you making room in your schedule. Also, many thanks for all your efforts. My initial inquiry is somewhat of a policy matter meant for Francis — my apologies for handing you the tougher one. Then my second involves a few small clarifications for Sam, so Sam gets the simpler item. Francis, when you talk things over with your policy groups, and you consider the rules that keep appearing, how do you see the route toward academic labs reopening? That doesn't automatically match what occurs when universities reopen, so there are several operational ramp questions mixed in. Another issue concerns what counts as "essential." I realize Dan Brennan raised a solid point regarding the schedules for those labs to reopen. As for Sam, the first one: how do you expect micro-arrays to advance going forward? Does the path feel any different at present, given the circumstances, compared with what you anticipated entering the year? Then Sam, might you comment on how stocking balances against shipment delays related to COVID, and whether COVID ended up being a net positive or negative for the quarter — there's been some debate about stocking out there. Many thanks.
Francis deSouza
executiveThank you, Steve. I appreciate your remarks too. Let me begin by addressing what we anticipate regarding the point when academic labs return to full capacity, and you brought up how we view universities reopening as opposed to research labs opening, along with those schedules. To start, I'll say our expectations for lab activity this quarter are quite modest; that's the assumption we've built in. You raised a key issue — we keep hearing from our customers that they'll probably reopen sooner than universities will. A great many universities are planning in phases, and that serves as the threshold for reopening. It differs from the threshold for bringing every undergraduate student, particularly, back onto campus. Thus we believe academic research labs and universities will reopen even before the entire universities reopen. Another factor at play is that numerous top academic research labs are deeply engaged in COVID-19 research. That holds everywhere, whether you consider Johns Hopkins, Yale, or Stanford. Consequently, the work they perform is essential. As a result, many of them will be operating before the wider reopening of academic labs at universities. So that's how the phasing goes. In my view, first you'll see academic labs currently centered on COVID-19 starting to expand, particularly once funding begins to slow. After that, you'll see broader academic labs reopening, and last, you'll see universities reopening to students, most likely.
Sam Samad
executiveYeah, Steve, regarding those adjustments you brought up — first off, when it comes to micro-array, micro-arrays are clearly going to face a big challenge in Q2, same as the rest of our business, based on what we said in our prepared remarks and for the full year. But speaking specifically to DTC, I'd say that first, it keeps shrinking as a share of our overall business, yet DTC is absolutely going to take a significant hit, perhaps even outsized, because as we observed in China in Q1, despite being a minor piece of the business, saliva shipments were basically prohibited. That meant you simply couldn't run testing for DTC. On top of that, some of the marketing typically tied to sporting events, the Olympics, and so on — all of that has now been postponed. So my view is DTC will be hit disproportionately too, even though it's now a really small piece of our business. As for the stocking, the net effect we cited of $20 million — that came from a negative $24 million impact on instruments; so during the last two weeks, we clearly saw customers holding off on capital purchases, and that produced a negative $24 million impact, while there was a plus $4 million impact, a positive one, from stocking on consumables; so overall a minor effect on consumables. Therefore, the net impact came to $20 million negative. And as you can tell, all of this was instruments, offset by a quite small amount of consumable stocking.
Doug Schenkel
analystAfternoon, and thanks for fielding my questions. From what you laid out during your prepared remarks, it sounds as though you're saying China keeps bouncing back, though not up to the marks we hit earlier in the prior year. Then, beyond China, it sounds as though you're painting a picture where, at minimum by the close of April, across every end market, things were leveling off. I simply want to confirm that reading is accurate, and, extending from there, is there anywhere worth flagging — whether by geography or by end market — that is still getting worse? And on the flip side of that, is anywhere clearly getting better beyond China? Thanks.
Francis deSouza
executiveUnderstood. Doug, thanks for raising that. Your read is precisely on target. What we're observing is that China's size business got hit first, yet it has unquestionably begun shifting direction and keeps building. In the same way, looking at the remaining parts of the globe, beginning in the final couple of weeks of March, a decline did appear. That decline came more sharply within the research market and arrived more gently within the clinical market, yet both appear to have leveled off, and certainly, examining the data points from the most recent week, you can begin to notice them at minimum — seem to indicate a gradual rebuilding. Regarding places where we anticipate recovery to land above average or below average, the ones proving resilient are the clinical areas — NIPT most particularly, plus oncology testing too; those did lose pace, but lost pace less quickly, and they have leveled off at a higher point compared with the remaining segments we've observed. Those are likewise markets where we anticipate a faster rebuild, given how urgent certain testing is within them. We talked — we went over a great deal concerning the research markets, namely that shelter-in-place mandates will hold academic labs back from reopening, and most of them will play out that way during this quarter, even though a number of those labs have now been repurposed toward COVID-19 research; therefore, we anticipate added business stemming from that research in those markets. And as I see it, one market that may prove slower to bounce back could be the direct-to-consumer market, precisely owing to the factors Sam mentioned previously.
Jacquie Ross
executiveHi Brandy — you're up next for a question, so I'll just jump in here. A quick reminder: in the script we noted that a sequential increase was indeed observed. When we look at the run volume figures for research as well as clinical in the most recent week we have, they actually showed a week-over-week sequential gain. That's an encouraging signal. It's only a single data point, of course. We'll clearly be watching for additional data points that back up that trend, but it's something that leaves us feeling a good deal of optimism.
Derik De Bruin
analystHi, good afternoon, everyone.
Francis deSouza
executiveHi, Derik.
Derik De Bruin
analystSo, if I can, I'll ask something with several parts. The first is simple — just put a figure on how big the licensing agreements were that helped services, since that amount came in a bit above what we had expected. Second, could you say a little about how instrument orders are trending — are they still arriving? Have you noticed any slowdown, just some broad sense of your order pipeline at the moment, obviously given that you don't — you currently have no salespeople in the field; and the other one is how much inventory and consumables your customers typically keep on hand. And the reason I ask is because, obviously, you're going to have labs closed and yet still consuming things. So it becomes a matter of when do we kind of see consumables pick up as conditions recover, and what is the shelf life there? I'm just kind of wondering what the usual dynamics are and how we should think about customers working through their stock before they begin — before they begin placing new orders. Do we hit an air pocket? So I'm just sort of trying to work through how that plays out? Thank you.
Sam Samad
executiveYes. So when it comes to the licensing revenues, Derik, we aren't disclosing precisely what the amount of the licensing revenues was, for sequencing and other. But what I can say is, we had certain licensing revenues included in our guidance that came through in Q1. As you saw, we had growth in that line, and it landed somewhat above expectations; so that's the situation there. Also, on the licensing revenues, this ties to some deals from last year, and typically those aren't necessarily all recognized when you design them. Some get recognized later, depending on various milestones and particular revenue recognition principles. So that answers the first question. What was the second question? As for the shelf life of consumables, I'll go to that. Basically the shelf life is generally about six months to nine months in effect. So that's typically what customers hold, in terms of what our consumable shelf life is; and what was the third question Derik had.
Francis deSouza
executiveRegarding the third question about consumable inventory: typically, how much do customers keep on hand, and what's the reorder timeframe? I'll interpret that as customers generally holding roughly 8 months of inventory, and just to remind everyone, for many of our reagents, shelf life runs about 6 months. Now, adding a bit more detail on how system ordering works. For sure, during the first 2 months of the quarter, system ordering was quite robust. Actually, linearity was stronger than usual. And we were on track for a solid quarter when it came to system orders, so even there, and so with the numbers. So from a systems orders standpoint, it was a strong quarter heading into the final 2 weeks of March.
Jacquie Ross
executiveAs Sam said before, that trend has carried over into the second quarter, I believe. Correct? So the orders that haven't shipped yet during this quarter are somewhat above what you'd typically expect from normal linearity. We're getting orders from customers in both clinical and research areas, though right now the momentum we've observed has actually come from research. Naturally, with just one month of data, that might shift, but that's what we're seeing.
Puneet Souda
analystYes. Hi, Francis. Thank you, and thank you for the crucial work you're doing during the pandemic. So first — if I could return to instruments once more, I was hoping you might expand on what you've observed, or what the team has observed, during previous downturns? In your view, what is the appetite for buying instruments among academic customers, and in those situations where people are being furloughed right now, and once they're back in the lab, what should we expect there? Then, looking at diagnostic customers, what's expected sort of in the second half, when things potentially are anticipated to go back to normal, and we keep hearing about pent-up demand along with obviously major trial shutdowns, with new enrollment dropping somewhere between 50% and 70%. So when we consider biopsy reaching the sequencer, how should instrument purchases be viewed within that context? And if I could also — if I could ask a second one, just briefly, about clarifying run versus revenue, I just wanted to grasp the run figures you gave, how should — what kind of arrow bar ought we to apply there? Are these counts of runs, or are these runs already reflecting or including how long the runs last, and therefore including the sequencing volumes you have? Thank you.
Francis deSouza
executiveSure. Thank you, Puneet. So let me make my way toward those questions; regarding the appetite for buying instruments, as Jacquie mentioned, they were performing strongly throughout most of Q1, and we were on pace for a really strong systems quarter in Q1. And they're beginning to perform strongly once more in Q2, during Q2's first month. The disruption we experienced wasn't in orders, but mainly in shipments, because, during Q1's final two weeks, what occurred was that a number of labs had shelter-in-place requirements and frankly simply weren't physically present to be able to accept the instruments from their orders. And so the disruption wasn't really in ordering activity, it was far more in shipments activity. And as we speak with our customers, what they tell us is that the appetite for instruments is entirely driven by the demand they're seeing, correct? So if you speak with our NIPT customers or oncology testing customers, they order according to the demand they're getting, driven by how many pregnancies are covered and oncology testing, and they expect that to recover. So they're saying we saw a slight dip, but this is central testing and so this shouldn't change, and that is entirely what determines whether they get instruments or not. So we aren't seeing hesitation regarding capital purchases or capital spend; it truly is driven by demand. And the same thing is occurring on the academic side, right. Thus, the extra work they’ve got is what pushes this. To receive those deliveries, they must return to the labs, so timing of when shipments actually occur becomes a limiting element, and that appears in revenue. Our expectation is that for most of Q2 they will remain sheltered. Yet looking past that point, budgets exist that they must use, the work they’re engaged in continues, and there is now additional effort tied to COVID research that will call for new instruments too.
Francis deSouza
executiveRegarding how many runs there were. Sorry, allow me to wrap up the final portion of what Puneet asked, which concerned run counts. So what we're providing to you is genuinely only the quantity of runs. It isn't tied to what kind of run it was, nor the outset data for any given run, and definitely not the expense for each run. Therefore, no straight link exists to revenue, though it does offer you a feel for how much activity is happening in our business.
Sam Samad
executivePuneet, this shows that we don't have every one of our devices hooked up — rather, it shows that a share of our devices are, with AMR sitting at the top for connectivity. Europe comes in second, APJ after that, and connectivity in China is quite minimal. So while it serves as an approximation, it's still a solid signal regarding the trajectory we're observing when it comes to the business bouncing back.
Dan Arias
analystHey, good afternoon everyone, and thanks. Francis, I'd like to stay on PopSeq, but shift away from the programs that are currently active toward the ones that were basically parked in the planning and design phase — could you speak to those? What I'm getting at is whether those are so complicated that a delay is simply to be expected, if we're talking about big health networks, or whether it might be the opposite. In other words, is the pandemic essentially acting as a pitch for pooling genomic health data? I'm curious what the following round of those efforts looks like.
Francis deSouza
executiveSure. Dan, let me walk through what we're observing regarding how things are unfolding across those efforts. When an effort sits in the planning phase, much of that planning work can still get done while the key people are staying safe at home; as a result, whatever tasks can be handled remotely keep progressing. We're noticing this even within the US with regard to the IDE submission for all of us; so when an effort truly remains in the planning phase, plenty of the work can keep going even through this stretch. Certain portions of a PopSeq ramp up might take a hit from the pandemic; for instance, if you happen to be in the middle of gathering samples, that's the kind of project component that would get held up, at least until folks began returning to the labs or heading back out into the field. There's another trend unfolding too: clearly, a COVID-19 dimension is becoming important to several of these population sequencing pushes; take, for instance, the effort Trevor Bedford led at the Fred Hutch in Seattle, which actually began life as a flu population research project before being redirected during the December, January, February window to hunt for COVID ID incidents, correct? So we're beginning to grasp how much these population efforts matter, both for helping fight the pandemic we're in now and for providing surveillance capacity against pandemics yet to come. That's what we see surfacing as part of the thinking behind the population sequencing efforts currently underway.
Patrick Donnelly
analystGreat, thank you. This one might be for you, Sam, regarding cost discipline. I definitely get that you want to keep a lid on spending for the time being, while also being set up to seize growth once we're past this. As you mentioned with staying nimble, if this does drag on, you've got programs ready to cut costs even more. So what would it take for you to go ahead with that — is there a particular window where, if shutdowns continue, you'd lean harder on the cost side? Could you walk us through those scenarios? Thanks.
Sam Samad
executiveYes. Thank you, Patrick. We've examined multiple scenarios, both to get a sense of how revenues could be affected this year and, clearly, how that plays into expenses. Let me start by saying that even during the first six months, based on where things stand right now and our current knowledge, we're removing a substantial amount of cost from the operation. During Q1, as you've heard, our spend came in at about $50 million under what we had projected. For Q2, we anticipate coming in at roughly $40 million under our projections for spend. So we're pulling a fair amount of cost out of the business, which mirrors certain steps taken on discretionary items — part of that comes from less travel, fewer conferences, people not attending, and so forth. Should this upheaval continue — and I'd rather not commit to a set number of months or a precise timeline — but if we come to believe that these shelter-in-place, work-from-home limitations are going to last through Q3 and past it, then we have contingency plans ready that call for us to take, I'd say, a far more aggressive approach to trimming expenses. That would mean moves such as halting hiring entirely. So, putting a stop to hiring, reviewing our contracts plus contract sales force and temp staff, reviewing a major decrease in capital expenditures, and a major decrease in projects outside of R&D. So it's wide-ranging in terms of what we'd cut, based on — again, that would require us to hold the view that the disruption will be longer and stretch definitely past Q3. That's how we're thinking about it.
Jacquie Ross
executiveBrandy, can we take the next one?
Sung Ji Nam
analystAppreciate you fitting me in. Francis, I believe you said the bulk of COVID-19 testing is going to run through PCR-based or serology methods. What I wanted to know is, given that we likely require an extraordinary volume of diagnostics across the coming 1 to 2 years, what stands out as the single largest obstacle? When it comes to sequencing capturing a greater portion of diagnostic testing, what's the main barrier? Would it be price, the installed base, or accuracy — could you address those? Thank you.
Francis deSouza
executiveYes, thanks for raising that. Right now, without question, PCR accounts for the vast majority of testing being performed. However, going forward, I believe it's reasonable to expect NGS testing to show up more in the market. And expect that to play out across several buckets. To begin with, you'll see a greater share of diagnostic testing for symptomatic people moving onto NGS technology. We're beginning to see a number of clear lots set up diagnostic testing that leverages NGS capability, so anticipate that growing in the future. The second development will be the arrival of ultra-high throughput capabilities, which we believe will be used for screening healthy people so they can return to work; consequently, a number of highly exciting concepts are being pursued by a number of customers regarding ways to screen extremely large populations of healthy individuals, giving employers confidence to bring their employees back into the workforce and giving schools confidence to bring their students back into schools. Now, effort is required to assemble those workflows, and that's precisely what's underway at present. Still, a great deal of activity is occurring in that space, since the capacity NGS could deliver and the cost per sample NGS could deliver might make that extraordinarily compelling. So that's the situation unfolding right now. In a similar vein, the following bucket where NGS testing can gain ground in the market is surveillance; in certain instances it's driven by CDCs globally. Yet other organizations are also assembling NGS capability to monitor how this outbreak is advancing. For that, NGS is required. That way you can understand how the virus is mutating. NGS is required so you can follow the geographic transmission of this virus, and that capability is beginning to come online. So when I consider diagnostic testing, screening and surveillance, you should anticipate NGS becoming a larger piece of the testing paradigm in the future than it represents today.
Vijay Kumar
analystHi everyone, thanks for taking my question. I've just got one quick follow-up. Francis, I believe you said the research side's run-rate had fallen 45, while clinical was maybe down in the high-teens. What I'd like to know is how your revenue splits between clinical and research, and where do things stand with capacity utilization on the systems? I'm asking because as we watch the economy reopen, is there available capacity, are these systems operating at 100%, and will there be some catch-up in the back half? Thank you.
Francis deSouza
executiveYes, sure. Looking at how our business breaks down on the sequencing consumable side, roughly 60% is research and 40% is clinical. When we consider the way the market bounces back, certain segments should see some recovery. Take the UK Biobank initiative, for instance—it was running at a full front model heading into March, and we anticipate some catch-up around that initiative. In the same way, cancer patients who were staying away from clinics to get tested—we expect some catch-up to occur there too. And perhaps a bit on the NIPT side as well. So there are certainly portions of our business where you can expect some catch-up. Still, in plenty of areas within our operations, we anticipate folks will return to complete what they had in progress. Because of that, it seems highly improbable that this work simply disappears. As a result, most of what we do will resume, and in certain instances, there will even be some making up for lost time.
Jacquie Ross
executiveAppreciate that, Brandy. Just a note that you'll be able to catch a webcast replay of today's call over in the Investors area of our site, and the dial-in details are also included in the earnings release we put out today. Thanks for being with us. That wraps up this call, and we're eager to share our next update once the second quarter has closed.
Operator
operatorThis concludes today’s conference call. You may now disconnect. Thank you for your participation.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Illumina, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Illumina, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Illumina, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.